Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart Ellenbroek

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 3, 2008
The dopamine agonist apomorphine differentially affects cognitive performance in alcohol dependent patients and healthy controlsArnt F A Schellekens, Armand W A A van Oosterwijck, Bart Ellenbroek, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 24, 2017
Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's DiseaseEdilio Borroni, Bernd Bohrmann, Fiona Grueninger, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 3, 2008
The dopamine agonist apomorphine differentially affects cognitive performance in alcohol dependent patients and healthy controlsArnt F A Schellekens, Armand W A A van Oosterwijck, Bart Ellenbroek, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 24, 2017
Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's DiseaseEdilio Borroni, Bernd Bohrmann, Fiona Grueninger, et al.
Pageof 3